Personen

apl. Prof. Dr. Mathias Zink

E-Mail

 

 

Publikationen

Publikationen in peer-reviewed Zeitschriften seit 2006

TOP 5 Publikationen:

  1. Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 16(1):77-89.
  2. Weinbrenner A, Peus V, Inta D, Englisch S, Zink M. Risperidone-associated increase in triglyceride levels. Am J Psychiatry. 2009 166(1):113-4.
  3. Moberget T, Doan NT, Alnæs D, Kaufmann T, Córdova-Palomera A, Lagerberg TV, Diedrichsen J, Schwarz E, Zink M, Eisenacher S, Kirsch P, Jönsson EG, Fatouros-Bergman H, Flyckt L, KaSP , Pergola G, Quarto T, Bertolino A, Barch D, Meyer-Lindenberg A, Agartz I, Andreassen OA, Westlye LT. Cerebellar volume and cerebellocerebral structural covariance in schizophrenia: a multisite mega-analysis of 983 patients and 1349 healthy controls. Mol Psychiatry. 2017 May 16. [Epub ahead of print].
  4. Zink M, Englisch S. Schizophrenia treatment: an obstacle course. Lancet Psychiatry. 2016 3(4):310-12. Epub 2016 Feb 24.
  5. Braun U, Schäfer A, Bassett DS, Rausch F, Schweiger JI, Bilek E, Erk S, Romanczuk-Seiferth N, Grimm O, Geiger LS, Haddad L, Otto K, Mohnke S, Heinz A, Zink M, Walter H, Schwarz E, Meyer-Lindenberg A, Tost H. Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function. Proc Natl Acad Sci U S A. 2016 113(44):12568-12573.